The TRYbeCA-1 study is investigating the addition of eryaspase to chemotherapy compared with chemotherapy alone in this population. This trial may provide a new option for patients who progress on first-line treatment, according to Hammel, who is the principal investigator of the study. Read more. . .
An unmet need exists in the second-line treatment of patients with pancreatic adenocarcinoma, explained Pascal Hammel, MD, PhD. To address this, clinical trials are focusing on this setting, such as the TRYbeCA-1 study (NCT03665441) of the L-asparaginase-based therapy eryaspase (Graspa).